Oncology
Oncology
Advertisement
Michal Sheleg, PhDOncology | June 20, 2024
Dr. Michal Sheleg discusses the benefit of MAIT cells compared with conventional T cells in treating solid tumors.
View More
Rob DillardGynecologic Cancer | June 21, 2024
The FDA approved pembrolizumab with chemotherapy for adult patients with primary advanced, recurrent endometrial carcinoma.
Rob DillardHead and Neck Cancer | June 18, 2024
Primary care providers are highly involved in opioid prescribing for HNC survivors.
Nera Lopetegui-Lia, MDAdvancements in Oncology | June 14, 2024
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 13, 2024
Dr. Margaret Gatti-Mays explains what makes The Oncology Brothers' content so important for community oncologists.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 14, 2024
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 14, 2024
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 12, 2024
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Dr. Eric VachonBreast Cancer | June 11, 2024
A study examined the impact of relationship satisfaction and agreement between breast cancer survivors and their partners.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 12, 2024
Dr. Gatti-Mays talks about the importance of tailoring treatments to individual patients with breast cancer.
Rob DillardOncology | June 7, 2024
Scientists from Northwestern Medicine have made a huge step forward in the treatment glioblastoma.
Rob DillardAdvancements in Oncology | June 7, 2024
Dr. Margaret Gatti-Mays, who specializes in breast cancer, delivers key insights on many breast cancer-related topics.
Rob DillardAdvancements in Oncology | June 6, 2024
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Rob DillardAdvancements in Oncology | June 6, 2024
Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting.
Rob DillardASCO 2024 | June 6, 2024
Some patients are unaware that metastatic breast cancer is incurable and that their treatment has no established end date.
Rob DillardASCO 2024 | June 6, 2024
Edmonton Symptom Assessment System completion rates need to be improved in patients with HNC.
Rob DillardAdvancements in Oncology | June 6, 2024
The Oncology Brothers spoke with Dr. Margaret Gatti-Mays, who provided invaluable insights on hormone receptor-positive BC.
Rob DillardASCO 2024 | June 4, 2024
One year of immunotherapy is optimal for treating patients with advanced melanoma.
Rob DillardASCO 2024 | June 4, 2024
Pembrolizumab use is increasing among patients with recurrent cervical cancer.
Rob DillardASCO 2024 | June 3, 2024
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Latest News

June 21, 2024